Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Publication
, Journal Article
Armstrong, PW; Adams, PX; Al-Khalidi, HR; Hamm, C; Holmes, D; O'Neill, W; Todaro, TG; Vahanian, A; Van de Werf, F; Granger, CB ...
Published in: Am Heart J
March 2005
Duke Scholars
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
March 2005
Volume
149
Issue
3
Start / End Page
402 / 407
Location
United States
Related Subject Headings
- Survival Rate
- Single-Chain Antibodies
- Shock, Cardiogenic
- Research Design
- Randomized Controlled Trials as Topic
- Premedication
- Myocardial Infarction
- Multicenter Studies as Topic
- Injections, Intravenous
- Infusions, Intravenous
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, P. W., Adams, P. X., Al-Khalidi, H. R., Hamm, C., Holmes, D., O’Neill, W., … APEX-AMI Steering Committee, . (2005). Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J, 149(3), 402–407. https://doi.org/10.1016/j.ahj.2004.12.015
Armstrong, Paul W., Peter X. Adams, Hussein R. Al-Khalidi, Christian Hamm, David Holmes, William O’Neill, Thomas G. Todaro, et al. “Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.” Am Heart J 149, no. 3 (March 2005): 402–7. https://doi.org/10.1016/j.ahj.2004.12.015.
Armstrong PW, Adams PX, Al-Khalidi HR, Hamm C, Holmes D, O’Neill W, et al. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2005 Mar;149(3):402–7.
Armstrong, Paul W., et al. “Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.” Am Heart J, vol. 149, no. 3, Mar. 2005, pp. 402–07. Pubmed, doi:10.1016/j.ahj.2004.12.015.
Armstrong PW, Adams PX, Al-Khalidi HR, Hamm C, Holmes D, O’Neill W, Todaro TG, Vahanian A, Van de Werf F, Granger CB, APEX-AMI Steering Committee. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2005 Mar;149(3):402–407.
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
March 2005
Volume
149
Issue
3
Start / End Page
402 / 407
Location
United States
Related Subject Headings
- Survival Rate
- Single-Chain Antibodies
- Shock, Cardiogenic
- Research Design
- Randomized Controlled Trials as Topic
- Premedication
- Myocardial Infarction
- Multicenter Studies as Topic
- Injections, Intravenous
- Infusions, Intravenous